Nigel Kay Spurr

Title: The Innovations of Nigel Kay Spurr

Introduction

Nigel Kay Spurr is a notable inventor based in Bishops Stortford, GB. He has made significant contributions to the field of cancer research through his innovative patents. With a total of 2 patents, his work focuses on the diagnosis and treatment of cancer susceptibility.

Latest Patents

One of Nigel's latest patents is titled "Diagnosis of susceptibility to cancer and treatment thereof." This patent outlines a method for determining a patient's susceptibility to cancer by obtaining a sample containing nucleic acid and contacting it with a nucleic acid capable of selectively hybridizing to a specific region of human chromosome 10. This region is defined by the markers D10S541 and D10S215. The patent emphasizes the importance of identifying a prostate tumor suppressor gene in this process. Another significant patent is related to a genetic assay that identifies polymorphisms at specific positions of the cytochrome P450 enzyme bufuralol-1'-hydroxylase. These polymorphisms are indicative of extensive metabolizer or poor metabolizer phenotypes, which are crucial for calculating safe or effective drug doses for individuals.

Career Highlights

Nigel Kay Spurr is associated with Imperial Cancer Research Technology, Ltd., where he applies his expertise in cancer research and innovation. His work has contributed to advancements in understanding cancer susceptibility and treatment options.

Collaborations

Nigel has collaborated with notable colleagues, including Charles Roland Wolf and John Stephen Miles. Their combined efforts have furthered research in the field of cancer diagnostics and treatment.

Conclusion

Nigel Kay Spurr's contributions to cancer research through his patents demonstrate his commitment to improving patient outcomes. His innovative methods for diagnosing cancer susceptibility and understanding drug metabolism are vital in the ongoing fight against cancer.